Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services Task Force

@article{Chou2016ScreeningFD,
  title={Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services Task Force},
  author={Roger Chou and Tracy L Dana and Ian Blazina and Monica Daeges and Christina Bougatsos and Thomas L Jeanne},
  journal={Annals of Internal Medicine},
  year={2016},
  volume={165},
  pages={560-564}
}
Dyslipidemia affects about 53% of U.S. adults (105.3 million) (1). Although dyslipidemia becomes more prevalent with age, it also affects younger adults. About 36% of adults aged 20 to 29 years and 43% aged 30 to 39 years meet levels recommended by the National Cholesterol Education Program for all lipids (2). Dyslipidemia is associated with cardiovascular disease, the leading cause of death in the United States. In 2010, the prevalence of coronary heart disease (CHD) was 1.2% among those aged… 
Question: In men with risk factors for coronary artery disease, does initiating lipid screening earlier than 35 years of age reduce cardiovascular events?
TLDR
An updated systematic review of USPSTF recommendations from 2008 concluded that there were no identified studies on benefits or harms of treatment versus no treatment regarding cardiovascular outcomes in adults aged 21 to 39 years.
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
TLDR
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older.
Effect of Change in Total Cholesterol Levels on Cardiovascular Disease Among Young Adults
TLDR
The findings of this study indicate that increased cholesterol levels were associated with high CVD risk in young adults, and young adults with decreased cholesterol levels had reduced risk for CVD.
Cholesterol Evaluation in Young Adults: Absence of Clinical Trial Evidence Is Not a Reason to Delay Screening
TLDR
The authors suggest that their findings not only support the more conservative USPSTF approach but provide further rationale to delay screening until age 40 years for men and 50 years for women, unless additional atherosclerotic risk factors are present.
Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys
TLDR
The prevalence of elevated 10-year ASCVD risk in young adults is identified in several subgroups based on age, sex, smoking status, and the presence of hypertension by extrapolating the pooled cohort risk prediction equation to a nationally representative sample of adults aged 30 to 49 years.
Association of four lipid components with mortality, myocardial infarction, and stroke in statin-naïve young adults: A nationwide cohort study
TLDR
For statin-naïve young adults, the risk of clinical events was proportional to lipid levels, positively with TC and triglycerides, negatively with HDL-C, and J-shaped with LDL-C.
Prevalence of dyslipidemia in young adults.
TLDR
Dyslipidemia is a major risk factor for numerous systemic disorders and should be detected early in life for effective management before the appearance of symptoms, with females being more frequently affected than females.
CHARACTERISTICS OF THE LIPID PROFIL YOUNG ADULTS WITH ISCHEMIC HEART DISEASE IN GEORGIAN POPULATION
TLDR
Investigation of lipid profile indices in young adults in Georgian population found lipid indices TC-HDL/ HDL, TG /HDL, and LDL/HDL can be used for the primary diagnosis of ischemic heart disease in young adult.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
Changes in serum total cholesterol levels over 18 years in a cohort of men and women: The Nijmegen Cohort Study.
TLDR
Over an 18-year period cholesterol level increased in most subjects, at a younger age in men than in women, and the highest increase in women took place during the menopausal period.
Screening for Lipid Disorders in Adults: Selective Update of 2001 US Preventive Services Task Force Review
TLDR
There is no new evidence relevant to screening younger adults or to appropriate screening intervals and the balance of benefits and harms is clearly in favor of statin therapy among individuals enrolled in some, but not all, randomized trials of primary prevention.
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
TLDR
These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians but also specialists from lipid clinics or metabolic units who are dealing with dyslipIDAemias that are more difficult to classify and treat.
Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia
TLDR
This study, the largest of its kind, permitted more precise and extensive determination of the CAD risk accompanying severe hyperbetalipoproteinemia than has heretofore been possible.
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial
TLDR
Cholesterol lowering with rosuvastatin 40 mg did not reduce the progression of AS in patients with mild to moderate AS; thus, statins should not be used for the sole purpose of reducing the progress of AS.
...
...